Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [41] Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Emma Zattarin
    Daniele Presti
    Luigi Mariani
    Caterina Sposetti
    Rita Leporati
    Alice Menichetti
    Chiara Corti
    Chiara Benvenuti
    Giovanni Fucà
    Riccardo Lobefaro
    Francesca Ligorio
    Leonardo Provenzano
    Andrea Vingiani
    Marta Del Vecchio
    Gaia Griguolo
    Marianna Sirico
    Ottavia Bernocchi
    Antonio Marra
    Paola Zagami
    Elisa Agostinetto
    Flavia Jacobs
    Pierluigi Di Mauro
    Andrea Esposito
    Carlo Alberto Giorgi
    Luca Lalli
    Laura Boldrini
    Pier Paolo Berton Giacchetti
    Ambra Carnevale Schianca
    Valentina Guarneri
    Rebecca Pedersini
    Agnese Losurdo
    Alberto Zambelli
    Daniele Generali
    Carmen Criscitiello
    Giuseppe Curigliano
    Giancarlo Pruneri
    Filippo de Braud
    Maria Vittoria Dieci
    Claudio Vernieri
    npj Breast Cancer, 9
  • [42] Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
    van Aken, Evert S. M.
    Beeker, Aart
    Houtenbos, Ilse
    Pos, Floris J.
    Linn, Sabine C.
    Elkhuizen, Paula H. M.
    de Jong, Monique C.
    CANCER REPORTS, 2022, 5 (02)
  • [43] CDK4/6 inhibitors for primary endocrine resistant HR-positive/ HER2-negative metastatic breast cancer: a case report
    Luo, Ting
    Zhu, Kunrui
    Zhong, Xiaorong
    He, Ping
    Yan, Xi
    Tian, Tinglun
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [44] Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
    Portman, Neil
    Alexandrou, Sarah
    Carson, Emma
    Wang, Shudong
    Lim, Elgene
    Caldon, C. Elizabeth
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : R15 - R30
  • [45] Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment
    Liu, Minghui
    Liu, Hongyu
    Chen, Jun
    ONCOLOGY REPORTS, 2018, 39 (03) : 901 - 911
  • [46] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. -S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K. L.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Petrakova, K.
    Hart, L. L.
    Villanueva, C.
    Chan, A.
    Jakobsen, E.
    Nusch, A.
    Burdaeva, O.
    Grischke, E. -M.
    Alba, E.
    Wist, E.
    Marschner, N.
    Favret, A. M.
    Yardley, D.
    Bachelot, T.
    Tseng, L. -M.
    Blau, S.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    Hirawat, S.
    O'Shaughnessy, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1738 - 1748
  • [47] Ribociclib for HR-Positive, Advanced Breast Cancer REPLY
    Hortobagyi, Gabriel N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 289 - 289
  • [48] Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers
    Lim, B.
    Lee, L.
    Pearson, T.
    Liu, H.
    Hwang, M.
    Choi, K.
    Tripathy, D.
    Ueno, N. T.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S14 - S15
  • [49] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [50] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
12345